Clinical features and cognitive sequelae in COVID-19: a retrospective study on N=152 patients.
COVID-19
ICU
Neuropsychology
Premorbid
SARS-CoV-2
Steroid
Journal
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
ISSN: 1590-3478
Titre abrégé: Neurol Sci
Pays: Italy
ID NLM: 100959175
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
received:
11
10
2021
accepted:
11
11
2021
pubmed:
16
11
2021
medline:
6
1
2022
entrez:
15
11
2021
Statut:
ppublish
Résumé
The novel human coronavirus (SARS-CoV-2) shows neurotropism and systemically affects the central nervous system (CNS). Cognitive deficits have been indeed reported as both short- and long-term sequelae of SARS-CoV-2 infection. However, the association between these disturbances and background/disease-related clinical features remains elusive. This work aimed at exploring how post-infective cognitive status relates to clinical/treatment outcomes by controlling for premorbid/current risk factors for cognitive deficits. Cognitive measures (Mini-Mental State Examination, MMSE) of N=152 COVID-19 patient were retrospectively assessed in relation to disease severity, intensive care unit (ICU) admission, steroidal treatment, and occurrence of other viral/bacterial infections by controlling for remote/recent/COVID-19-related risk factors for cognitive deficits (at-risk vs. not-at-risk: Neuro+ vs. Neuro-). Descriptively, impaired MMSE performances were highly prevalent in mild-to-moderate patients (26.3%). ICU-admitted patients made less errors (p=.021) on the MMSE than those not admitted when partialling out risk factors and age-the latter negatively influencing performances. When addressing Neuro- patients only, steroidal treatment appears to improve MMSE scores among those suffering from other infections (p=.025). Cognitive sequelae of COVID-19 are likely to arise from a complex interplay between background/clinical premorbid features and disease-related/interventional procedures and outcomes. Mild-to-moderate patients requiring assistive ventilation who however are not admitted to an ICU are more likely to suffer from cognitive deficits-despite their etiology remaining elusive.
Sections du résumé
BACKGROUND
BACKGROUND
The novel human coronavirus (SARS-CoV-2) shows neurotropism and systemically affects the central nervous system (CNS). Cognitive deficits have been indeed reported as both short- and long-term sequelae of SARS-CoV-2 infection. However, the association between these disturbances and background/disease-related clinical features remains elusive. This work aimed at exploring how post-infective cognitive status relates to clinical/treatment outcomes by controlling for premorbid/current risk factors for cognitive deficits.
METHODS
METHODS
Cognitive measures (Mini-Mental State Examination, MMSE) of N=152 COVID-19 patient were retrospectively assessed in relation to disease severity, intensive care unit (ICU) admission, steroidal treatment, and occurrence of other viral/bacterial infections by controlling for remote/recent/COVID-19-related risk factors for cognitive deficits (at-risk vs. not-at-risk: Neuro+ vs. Neuro-).
RESULTS
RESULTS
Descriptively, impaired MMSE performances were highly prevalent in mild-to-moderate patients (26.3%). ICU-admitted patients made less errors (p=.021) on the MMSE than those not admitted when partialling out risk factors and age-the latter negatively influencing performances. When addressing Neuro- patients only, steroidal treatment appears to improve MMSE scores among those suffering from other infections (p=.025).
DISCUSSION
CONCLUSIONS
Cognitive sequelae of COVID-19 are likely to arise from a complex interplay between background/clinical premorbid features and disease-related/interventional procedures and outcomes. Mild-to-moderate patients requiring assistive ventilation who however are not admitted to an ICU are more likely to suffer from cognitive deficits-despite their etiology remaining elusive.
Identifiants
pubmed: 34779965
doi: 10.1007/s10072-021-05744-8
pii: 10.1007/s10072-021-05744-8
pmc: PMC8591589
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
45-50Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2021. Fondazione Società Italiana di Neurologia.
Références
Restor Dent Endod. 2013 Feb;38(1):52-4
pubmed: 23495371
Neurol Sci. 2022 Jan;43(1):81-84
pubmed: 34668124
Neurol Sci. 2022 Feb;43(2):979-984
pubmed: 34184168
Neuropsychology. 2021 May;35(4):335-351
pubmed: 34043385
N Engl J Med. 2020 Jun 4;382(23):2268-2270
pubmed: 32294339
Front Neurol. 2021 May 17;12:643646
pubmed: 34079511
J Psychiatr Res. 2020 Oct;129:98-102
pubmed: 32912598
Neuropsychopharmacology. 2021 Dec;46(13):2235-2240
pubmed: 33589778
Front Psychiatry. 2021 Feb 10;11:621773
pubmed: 33643083
Ther Clin Risk Manag. 2020 Jun 30;16:595-605
pubmed: 32669846
PLoS One. 2021 Feb 8;16(2):e0246590
pubmed: 33556127
J Neurol. 2021 Dec;268(12):4422-4428
pubmed: 33932157
Neurol Sci. 2021 Jun;42(6):2273-2281
pubmed: 33846880
Clin Neuropsychol. 2020 Oct - Nov;34(7-8):1453-1479
pubmed: 32901580
Aging Clin Exp Res. 2022 Feb;34(2):375-382
pubmed: 34313961
J Nucl Med. 2021 Jul 1;62(7):910-915
pubmed: 33789937
ACS Chem Neurosci. 2020 Apr 1;11(7):995-998
pubmed: 32167747
Brain Commun. 2020 May 28;2(2):fcaa069
pubmed: 33074266
J Neurol Neurosurg Psychiatry. 2021 May;92(5):567-568
pubmed: 33219042
Brain Behav Immun Health. 2020 Dec;9:100163
pubmed: 33111132
Neuropsychol Rehabil. 2020 Oct;30(9):1625-1628
pubmed: 32869697
JAMA Neurol. 2020 Aug 1;77(8):1018-1027
pubmed: 32469387